Health-related Quality of Life Among Comorbidity Patients With Type 2 Diabetes Mellitus and Hypertension.

Background: Evaluating the Health-Related Quality of Life (HRQoL) in patients with hypertension and diabetes is vital for improving treatment adherence and outcomes.

Objective: This study assessed HRQoL and its influencing factors among patients with both type 2 diabetes mellitus and hypertension at Can Tho Hospital, Vietnam.

Methods: A cross-sectional study was performed on 310 outpatients at the polyclinic, using the Short Form-36 Health Survey (SF-36) between July 2021 and July 2022.

Treatment initiation and completion among head and neck squamous cell carcinoma patients in Tanzania.

Objective: Few studies characterizing clinical outcomes of head and neck cancer (HNC) patients in sub-Saharan Africa report the proportion of patients who initiate and complete treatment, information integral to contextualizing survival outcomes. This retrospective cohort study describes HNC patients who presented to Muhimbili National Hospital and Ocean Road Cancer Institute in 2018, the highest-volume oncology tertiary referral centers in Tanzania. Logistic regression was applied to assess predictors of treatment initiation and completion.

Optimization of meropenem continuous infusion based on Monte Carlo simulation integrating with degradation study.

Objective: Meropenem degradation poses a challenge to continuous infusion (CI) implementation. However, data about the impact of degradation on the probability of target attainment (PTA) of meropenem has been limited. This study evaluated the stability of meropenem brands and the consequence of in-bottle degradation on PTA in different environmental scenarios.

Neutrophil-to-Lymphocyte Ratio and Pembrolizumab Outcomes in Oral Cavity Squamous Cell Carcinoma.

Objective: To determine the relationship between pretreatment neutrophil-to-lymphocyte ratio (NLR) and 6-month progression-free survival (PFS)/2-year overall survival (OS) among patients with recurrent or metastatic (R/M) oral cavity cancer on pembrolizumab.

Study Design: This study was a retrospective, observational study performed at a tertiary care academic center.

Setting: Participants included patients with oral cavity squamous cell carcinoma (OCSCC) who began pembrolizumab treatment at the University of California, San Francisco between May 2016 and May 2022.

Oncological Outcomes of Patients With Oral Potentially Malignant Disorders.

Importance: Understanding the clinical course and malignant transformation rate of oral potentially malignant disorders (OPMDs)-including oral leukoplakia, oral erythroplakia, oral submucous fibrosis, and oral lichen planus-is crucial for early detection and improved survival rates in patients with oral cancer.

Objective: To evaluate the progression of oral cancer from OPMDs using a large US electronic medical database.

Design, Setting, And Participants: This retrospective cohort study used data from the University of California, San Francisco's PatientExploreR database between January 1973 and March 2024.